Fintech PR
Alan Kirshner, former Chairman and CEO of Markel Group, passes away
RICHMOND, Va., March 19, 2024 /PRNewswire/ — Alan Kirshner, 88, former Chairman of the Board and Chief Executive Officer (CEO) of Markel Group Inc. (NYSE: MKL), passed away on March 17, 2024.
Kirshner joined Markel in 1960 and played a substantial role in transforming the company from a privately held regional insurer to a family of businesses with global reach. He joined the Board of Directors in 1978 and became Chairman and CEO in 1986, the same year Markel became a public company. Kirshner served as CEO through 2015, became Executive Chairman in 2016, and then became Chairman Emeritus in 2020. Over that period, the company grew from less than 300 associates to more than 20,000 today.
“This is a sad day,” said CEO Tom Gayner. “It’s hard to put into words the legacy and impact of Alan Kirshner. He was as savvy and hard-working a leader as anyone I ever met, but it was his commitment to people that really set him apart. Alan was by nature a builder and dedicated his life to building a company that could serve others for generations to come. In doing so, he taught us that there is nothing more important in business and life than treating people with kindness and respect. It’s a lesson and legacy that we’ll never forget.”
Kirshner was the lead author of a cultural creed that the company calls the Markel Style. The statement, which stands unchanged since being written in 1986, captures the values that define Markel Group’s culture—including their zealous pursuit of excellence, sense of humor, honesty, disdain for bureaucracy, and commitment to communities. The latter of which Kirshner reinforced with his own community investments, including starting the Faison School for autistic children and the Partnership for the Future program to help students in underserved communities attend college.
“Words alone cannot express my gratitude for having been his friend and partner for the last 64 years,” said Vice Chairman Tony Markel. “He was the consummate leader…kind, caring, generous, respectful, and above all a great listener. As the author of the Markel Style, his legacy is assured endurance.”
Chairman of the Board Steve Markel added, “I worked side-by-side with Alan for nearly five decades. He was a visionary, challenging leadership and the organization to embrace change, innovate, create, and strive for a better way. Through the Markel Style, his spirit and principles will live forever within Markel Group.”
About Markel Group
Markel Group Inc. (NYSE: MKL) is a diverse family of companies that includes everything from insurance to bakery equipment, building supplies, houseplants, and more. The leadership teams of these businesses operate with a high degree of independence, while at the same time living the values that we call the Markel Style. Our specialty insurance business sits at the core of our company. Through decades of sound underwriting, the insurance team has provided the capital base from which we built a system of businesses and investments that collectively increase Markel Group’s durability and adaptability. It’s a system that provides diverse income streams, access to a wide range of investment opportunities, and the ability to efficiently move capital to the best ideas across the company. Most importantly though, this system enables each of our businesses to advance our shared goal of helping our customers, associates, and shareholders win over the long term. Visit mklgroup.com to learn more.
Logo – https://mma.prnewswire.com/media/2077105/Markel_Group_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/alan-kirshner-former-chairman-and-ceo-of-markel-group-passes-away-302092893.html
Fintech PR
Multi-Use Bioreactor Market in Pharmaceuticals and Research Institutions to Hit USD 12.26 Billion by 2029, Growing 9.7% Annually | Valuates Reports
BANGALORE, India, March 13, 2025 /PRNewswire/ — Multi Use Bioreactor Market is Segmented by Type (Manual, Automatic, Semi-Automatic), by Application (Pharmaceuticals, Scientific Research Institution).
According to new survey, Global Multi Use Bioreactor Market is projected to reach USD.
12260 Million in 2029, increasing from USD 6415 Million in 2022, with a CAGR of 9.7% during the period of 2023 to 2029.
Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-37Q12337/Global_Multi_Use_Bioreactor_Market
Major Factors Driving the Growth of Multi Use Bioreactor Market:
The multi-use bioreactor market is experiencing sustained growth, driven by advancements in biopharmaceutical production, automation, and process optimization. These systems play a vital role in scaling up biologics manufacturing while maintaining cost efficiency and regulatory compliance. Market players are investing in next-generation bioreactor technologies to enhance productivity and meet evolving industry demands.
The integration of artificial intelligence, real-time monitoring, and hybrid bioprocessing solutions is transforming biomanufacturing practices. As personalized medicine and cell-based therapies gain traction, the demand for flexible and high-performance bioreactors is expected to rise. The continuous expansion of global bioprocessing infrastructure reinforces the market’s long-term growth trajectory, positioning multi-use bioreactors as indispensable assets in pharmaceutical and biotechnology sectors.
Unlock Insights: View Full Report Now! https://reports.valuates.com/market-reports/QYRE-Auto-37Q12337/global-multi-use-bioreactor
TRENDS INFLUENCING THE GROWTH OF THE MULTI USE BIOREACTOR MARKET:
Semi-automatic bioreactors play a crucial role in biopharmaceutical research and industrial fermentation processes by offering a balance between manual control and automation. These systems enable users to adjust key parameters such as temperature, pH, and oxygen levels while leveraging automated controls for consistency. The flexibility of semi-automatic bioreactors makes them ideal for academic institutions, pilot-scale production, and laboratories requiring cost-effective solutions. Their ability to accommodate a wide range of microbial and cell culture processes attracts pharmaceutical companies looking for adaptable production methods. The increasing demand for customized bioproduction, including cell therapy and regenerative medicine, further propels the adoption of semi-automatic bioreactors. These factors drive market growth and expand bioprocessing capabilities globally.
Automatic bioreactors are revolutionizing large-scale biomanufacturing by integrating advanced sensors, AI-driven monitoring, and real-time data analytics. These systems optimize fermentation and cell culture processes, reducing human intervention while ensuring precision and reproducibility. The pharmaceutical industry heavily relies on automatic bioreactors for monoclonal antibody production, vaccine development, and protein synthesis. Their ability to maintain sterile conditions and minimize contamination risks makes them indispensable for biologics manufacturing. The growing trend of continuous bioprocessing and process intensification has further increased demand for automatic bioreactors, enabling high-throughput production. Additionally, biopharma firms are investing in these systems to enhance scalability, reduce operational costs, and streamline regulatory compliance, fueling the expansion of the multi-use bioreactor market.
The pharmaceutical industry is a major driver of the multi-use bioreactor market, as bioreactors are essential for drug discovery, development, and commercial-scale manufacturing. Biopharmaceutical companies use these systems for cell culture applications, vaccine production, and biosimilar development. With the rise of personalized medicine and gene therapy, pharmaceutical firms are shifting toward modular and flexible bioreactor systems to meet evolving production demands. Regulatory agencies emphasize compliance with Good Manufacturing Practices (GMP), encouraging the adoption of high-quality multi-use bioreactors. Additionally, the rapid response to emerging diseases, such as COVID-19, has accelerated investments in bioreactor technology for vaccine research and development. This increasing reliance on bioreactors for pharmaceutical applications significantly contributes to market growth.
The growing prevalence of chronic diseases and the rise of biologics have fueled demand for biopharmaceuticals, driving the need for efficient multi-use bioreactors. As monoclonal antibodies, gene therapies, and biosimilars gain prominence, manufacturers require scalable bioprocessing solutions. Multi-use bioreactors allow efficient production while ensuring consistency and regulatory compliance. Their ability to support various cell lines and microbial cultures enhances flexibility in drug development. This surge in biologics manufacturing directly contributes to market expansion.
Although single-use bioreactors are gaining traction, multi-use bioreactors remain crucial due to their cost efficiency in large-scale production. Many facilities adopt hybrid systems combining single-use and stainless-steel bioreactors to maximize flexibility. Hybrid approaches allow manufacturers to balance cost savings with operational efficiency, reducing turnaround time while maintaining sterility. This transition toward mixed-use systems supports sustainable biomanufacturing and meets evolving industry needs.
The rise of personalized therapies, including CAR-T cell therapies and regenerative medicine, has necessitated adaptable bioprocessing solutions. Multi-use bioreactors support customized production of small-batch biologics tailored to individual patient needs. Their scalability and versatility make them ideal for emerging cell-based therapies. As precision medicine gains momentum, demand for bioreactors catering to specialized manufacturing continues to grow.
While single-use systems dominate small-scale applications, multi-use bioreactors remain cost-effective for high-volume biomanufacturing. Their ability to process large batches of biologics reduces per-unit costs, making them economically viable for commercial production. Established pharmaceutical companies leverage multi-use systems for blockbuster drug manufacturing, ensuring long-term cost savings. This economic advantage reinforces their continued market demand.
Claim Yours Now! https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-37Q12337&lic=single-user
MULTI USE BIOREACTOR MARKET SHARE
North America dominates the market due to the presence of leading biopharma companies, a robust research ecosystem, and significant government funding. Europe follows closely, with stringent regulatory standards and strong biomanufacturing capabilities.
Key Companies:
- Sartorius
- Thermo Fisher Scientific Inc
- General Electric
- Eppendorf
- Merck KGaA
- Pall Corporation
- ZETA
- Pierre Guerin
- Praj Hipurity Systems Limited
- Bioengineering AG
- Infors
- SOLARIS BIOTECHNOLOGY srl
- Bbi-biotech
- PBS Biotech;Inc.
- GEA Group Aktiengesellschaft
- CerCell A/S
Purchase Regional Report: https://reports.valuates.com/request/regional/QYRE-Auto-37Q12337/Global_Multi_Use_Bioreactor_Market
SUBSCRIPTION
We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.
DISCOVER MORE INSIGHTS: EXPLORE SIMILAR REPORTS!
– Perfusion Bioreactor market was valued at USD 703.66 Million in 2024 and is anticipated to reach USD 1,153.63 Million by 2031, witnessing a CAGR of 7.19% during the forecast period 2025-2031.
– Lab Scale Bioreactor market was valued at USD 2369 Million in 2023 and is anticipated to reach USD 4337.5 Million by 2030, witnessing a CAGR of 8.6% during the forecast period 2024-2030.
– Single-Use Bioreactors (SUB) Market was valued at USD 220 Million in the year 2024 and is projected to reach a revised size of USD 275 Million by 2031, growing at a CAGR of 3.3% during the forecast period.
– Bioreactors Market
– Pharmaceutical Fermentation Bioreactor market is projected to grow from USD 6256 Million in 2024 to USD 11080 Million by 2030, at a Compound Annual Growth Rate (CAGR) of 10.0% during the forecast period.
– Bioreactors and Fermentors Market
– Cell Culture Bioreactors Market
– Bubble Column Bioreactor Market
– Membrane Bioreactor Systems market was valued at USD 3307.4 Million in 2023 and is anticipated to reach USD 4996.5 Million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
– Fixed Bed Bioreactors Market
– Micro Bioreactors Market revenue was USD 133.9 Million in 2022 and is forecast to a readjusted size of USD 246.5 Million by 2029 with a CAGR of 9.0% during the forecast period (2023-2029).
DISCOVER OUR VISION: VISIT ABOUT US!
Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.
Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that’s why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.
To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources.
GET A FREE QUOTE
Valuates Reports
sales@valuates.com
For U.S. Toll-Free Call 1-(315)-215-3225
WhatsApp: +91-9945648335
Website: https://reports.valuates.com
Blog: https://valuatestrends.blogspot.com/
Pinterest: https://in.pinterest.com/valuatesreports/
Twitter: https://twitter.com/valuatesreports
Facebook: https://www.facebook.com/valuatesreports/
YouTube: https://www.youtube.com/@valuatesreports6753
https://www.facebook.com/valuateskorean
https://www.facebook.com/valuatesspanish
https://www.facebook.com/valuatesjapanese
https://valuatesreportspanish.blogspot.com/
https://valuateskorean.blogspot.com/
https://valuatesgerman.blogspot.com/
https://valuatesreportjapanese.blogspot.com/
Logo: https://mma.prnewswire.com/media/1082232/Valuates_Reports_Logo.jpg
View original content:
Company announcement No. 578, 2025
CEO Jörg Brinkmann have purchased shares in H+H International A/S
COPENHAGEN, Denmark, March 13, 2025 /PRNewswire/ — H+H International A/S has received notification pursuant to article 19 of EU Regulation no. 596/2014 of the below transaction(s) related to shares or other financial instruments in H+H International A/S made by persons discharging managerial responsibilities in H+H International A/S or persons closely related to them.
|
1.
|
Details of the person discharging managerial responsibilities/person closely associated
|
||
|
a)
|
Name
|
Jörg Brinkmann
|
|
|
2.
|
Reason for the notification
|
||
|
a)
|
Position/status
|
CEO
|
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
|
3.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
H+H International A/S
|
|
|
b)
|
LEI
|
LEI: 3800GJODT6FV8QM841
|
|
|
4.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Shares
DK0015202451
|
|
|
b)
|
Nature of the transaction
|
Purchase
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
DKK 110 per share |
2,000
|
||
|
d)
|
Aggregated information
– Aggregated volume
– Aggregated price
|
Aggregated information
2000 shares
DKK 220,000
|
|
|
e)
|
Date of the transaction(s)
|
2025-03-10
|
|
|
f)
|
Place of transaction(s)
|
Copenhagen (XCSE)
|
|
|
1.
|
Details of the person discharging managerial responsibilities/person closely associated
|
||
|
a)
|
Name
|
Jörg Brinkmann
|
|
|
2.
|
Reason for the notification
|
||
|
a)
|
Position/status
|
CEO
|
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
|
3.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
H+H International A/S
|
|
|
b)
|
LEI
|
LEI: 3800GJODT6FV8QM841
|
|
|
4.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Shares
DK0015202451
|
|
|
b)
|
Nature of the transaction
|
Purchase
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
DKK 107.6 per share |
2,000 |
||
|
d)
|
Aggregated information
– Aggregated volume
– Aggregated price
|
Aggregated information
2000 shares
DKK 215,200
|
|
|
e)
|
Date of the transaction(s)
|
2025-03-11
|
|
|
f)
|
Place of transaction(s)
|
Copenhagen (XCSE)
|
|
CONTACT:
For further information please contact:
Niclas Bo Kristensen
Head of Investor Relations & Treasury
+45 24 48 03 67
Nbk@hplush.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
578 – Transactions for persons discharging managerial responsibilities |
View original content:https://www.prnewswire.co.uk/news-releases/transactions-for-persons-discharging-managerial-responsibilities-302401339.html
Fintech PR
CBC Summit Expands to Europe, Bringing Crypto Banking, Compliance, and Payments Leaders Together in London on March 17, 2026
WASHINGTON, March 13, 2025 /PRNewswire/ — “CBC Summit is excited to announce the expansion of its highly successful US-based event to London on March 17, 2026.“
Introduced in 2023, CBC Summit USA has become a must-attend annual gathering in Washington, D.C., for crypto banking, compliance, and payments executives; featuring participation from industry leaders such as Coinbase, Kraken, Ledger, Binance, Elliptic, Stripe, Robinhood, Anchorage Digital Bank, Silicon Valley Bank, Ibanera, and BCB Group.
CBC Summit Europe marks a significant step in expanding the event’s global reach, offering professionals across Europe the opportunity to engage in high-level discussions on the latest trends, challenges, and solutions shaping the global crypto banking ecosystem.
CBC Summit Europe will provide a platform for over 100 European industry leaders, executives, and government agencies to engage in high-level discussions on the latest trends, challenges, and solutions shaping the global crypto banking ecosystem.
CBC Summit Europe topics will include:
- The current state of fintech and crypto banking in the UK and Europe – insights into the struggles and solutions to onboarding with crypto friendly banks for fiat on-ramp and off-ramp services in the UK and Europe.
- Building the new Financial Infrastructure – exchanges and partners are building out their own Layer 2 networks to ease transition to DeFi and map out a new financial infrastructure. What comes next?
- Navigating AML Challenges in the FCA & MiCA Era – adapting to evolving anti-money laundering regulations.
- Transforming Global Finance with Stablecoins & Cross-Border Payments – exploring their role in transforming global finance.
- Financial Crime Trends in Crypto & Fintech – What methods are criminals currently employing, and how is financial crime evolving in crypto?
“The expansion of CBC Summit USA to Europe reflects the growing importance of global collaboration in crypto banking, compliance, and payments” said Joshua Radbod, CEO of CBC Summit. “As the industry continues to evolve, bringing together global leaders from different regulatory environments is crucial for shaping its future.”
Registration & More Information: Registration is now open, and attendees are encouraged to secure their spots in advance. For more details on speakers, sessions, and sponsorship opportunities, visit https://www.cbcsummit.io/europe
About CBC Team: The CBC Team specializes in creating and operating events that address banking, compliance, and payments challenges in emerging industries. For more information, visit CBC Summit.
Media Contact: info@cbcsummit.io
View original content:https://www.prnewswire.co.uk/news-releases/cbc-summit-expands-to-europe-bringing-crypto-banking-compliance-and-payments-leaders-together-in-london-on-march-17-2026-302400124.html
-
Fintech6 days agoFintech Pulse: Your Daily Industry Brief – March 7, 2025 | Wise, Visa, Cadence, Unicredit, Aion Bank, Vodeno
-
Fintech7 days agoFintech Pulse: Your Daily Industry Brief – March 6, 2025 – Featuring Bolt, WSFS Bank, Greenlight, Bkash, Huawei, Meliuz
-
Fintech6 days agoHyPerform Receives ‘Excellence in Fintech’ Award at ET NOW Business Conclave & Awards 2025
-
Fintech PR6 days agoInnocan Pharma Announces Closing of Debenture Unit Offering to its Largest Shareholder, Tamar Innovest Limited
-
Fintech PR6 days agoMinesto selected to participate in GIA (Global Innovation Accelerator) programme by Swedish Energy Agency
-
Fintech PR6 days agoElliptic Data used by US Secret Service in Investigation into $96 Billion Russian Crypto Exchange Garantex
-
Fintech PR6 days agoApollo Group TV Expands Payment Options Making Premium Streaming More Accessible In 2025
-
Fintech3 days agoFintech Pulse: Your Daily Industry Brief – March 10, 2025 | Finovifi, Modern Banking Systems, France Flowdesk, Fintech Galaxy, ProgressSoft, Finory Investment, 1337 Ventures